Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Chodak

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Reviews in Urology|October 6, 2006
Prostate cancer: epidemiology, screening, and biomarkersGerald Chodak
Urology|February 1, 2003
Informed consent for prostate-specific antigen screeningSimon Wilkinson, Gerald Chodak
The Journal of Urology|June 18, 2004
The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomySimon Wilkinson, Gerald Chodak
European Urology|April 15, 2004
An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancerSimon Wilkinson, Gerald Chodak
Urology|August 30, 2003
Editorial panel on informed consent for PSA screeningAlistair R Ramsden, Gerald Chodak
Clinical Genitourinary Cancer|October 25, 2007
Combined androgen blockade in advanced prostate cancer: looking back to move forwardGerald Chodak, Leonard Gomella, De H Phung
Urology|February 25, 2003
Educating African-American men about prostate cancer: impact on awareness and knowledgeSimon Wilkinson, Marcy List, Michael Sinner, et al.
Urology|April 5, 2008
Do "rapid" PSA assays reduce anxiety and stress of prostate cancer patients undergoing regular review? A prospective evaluationSimon Wilkinson, Katherine Warren, Alistair Ramsden, et al.
Urology|April 16, 2013
Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trialPaul F Schellhammer, Gerald Chodak, James B Whitmore, et al.
The Journal of Urology|June 7, 2006
The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followupDavid G McLeod, William A See, Ira Klimberg, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Reviews in Urology|October 6, 2006
Prostate cancer: epidemiology, screening, and biomarkersGerald Chodak
Urology|February 1, 2003
Informed consent for prostate-specific antigen screeningSimon Wilkinson, Gerald Chodak
The Journal of Urology|June 18, 2004
The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomySimon Wilkinson, Gerald Chodak
European Urology|April 15, 2004
An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancerSimon Wilkinson, Gerald Chodak
Urology|August 30, 2003
Editorial panel on informed consent for PSA screeningAlistair R Ramsden, Gerald Chodak
Clinical Genitourinary Cancer|October 25, 2007
Combined androgen blockade in advanced prostate cancer: looking back to move forwardGerald Chodak, Leonard Gomella, De H Phung
Urology|February 25, 2003
Educating African-American men about prostate cancer: impact on awareness and knowledgeSimon Wilkinson, Marcy List, Michael Sinner, et al.
Urology|April 5, 2008
Do "rapid" PSA assays reduce anxiety and stress of prostate cancer patients undergoing regular review? A prospective evaluationSimon Wilkinson, Katherine Warren, Alistair Ramsden, et al.
Urology|April 16, 2013
Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trialPaul F Schellhammer, Gerald Chodak, James B Whitmore, et al.
The Journal of Urology|June 7, 2006
The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followupDavid G McLeod, William A See, Ira Klimberg, et al.
Pageof 2